Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02399215
Recruitment Status : Active, not recruiting
First Posted : March 26, 2015
Last Update Posted : December 18, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : December 1, 2020